Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BM219 phase I/II nebulized inhalation study in healthy adults and adults with COVID-19
ChiCTR2400094216Phase 2Completed
- Sponsor
- Changsha Third Hospital
- Start
- Dec 2024
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of BM219 in coronavirus disease 2019 (COVID-19) (11 arms), sponsored by Changsha Third Hospital. Primary endpoints: Safety: any adverse events occurring during the clinical study and Change from baseline in viral load in throat swabs at each time point. Started Dec 2024; status: completed.
02
Drugs
BM219
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2400094216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094216.